C. Ding
6 Papers
C. Ding is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has co-authored 6 publications.
Chat about Author
Papers
EP08.02-139 A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs
Shao-Hua Lu,Yan Zhang,G. Zhang,J. Zhou,Shundong Cang,Y. Cheng,G.Y. Wu,Pengfei Cao,Dashuai Lv,Hong Jian,C. Chen,X. Jin,P. Tian,K. Wang,G. Jiang,G.W. Chen,Qi Chen,H. J. Zhao,C. Ding,R.P. Guo,G. Sun,B. Wang,Z. Liu,J. Fang,J Yang,Wu Zhuang,Y. Liu,J.P. Zhang,J Chen,Q. Yu,M. Zhao,Jiuwei Cui,D. Li,Tienan Yi,Z. R. Yu,Y. Yang,X Zhi,Y. Huang,R. Wu,Li Chen,A. F. Zang,L. Cao,Q. Li,X Li,Yang Song,D. Wang,S. Zhang +46 more
TL;DR: Befotertinib (D-0316) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) as mentioned in this paper .
1
LBA57 Sintilimab plus anlotinib versus platinum-based chemotherapy as first-line therapy in metastatic NSCLC (SUNRISE): An open label, multi-center, randomized, phase II study
Baohui Han,T. Chu,Z. Yu,J. Wang,Y Zhao,Xiyan Mu,X. Yu,X Shi,Q. Shi,Michelle Guan,C. Ding,N. Geng +11 more
TL;DR: In this article , the authors presented the first phase Ⅱ randomized trial comparing sintilimab plus anlotinib with chemo in treatment-naïve metastatic NSCLC.
1
P-151 PRO-based symptom management for patients with gastric and esophageal cancer who have undergone previous surgery
Y He,S. Wu,C. Ding,L Fan,Lihong Ke,Y. Yuan,M. Li,Hui-qin Luo,X Hu,Jiayu Niu,H. Li,H Xu,W. Chen,Lei Cao +13 more
TL;DR: Wang et al. as mentioned in this paper found that after 16 weeks of symptom management, the number of overall symptoms in the PRO group was significantly lower than in the conventional care group (1 (0-1) vs 2.5 (1-4), P < 0.
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment for chronic lymphocytic leukemia/ small lymphocytic leukemia: a single‐arm study
M. Yi,Ye Xia,Yang Sha,Shu-Chao Qin,R. Jiang,Tonglu Qiu,Jin-Yin Qiu,Y. Yang,C. Ding,Y. Wu,L. Fan,W. Xu,J Y Li,Hu Zhu +13 more
TL;DR: In this paper , the BTK inhibitors (BTKi) monotherapy has introduced the concept of continuous treatment in CLL/SLL until disease progression, leading to several concerns like lack of deep remission, increasing risk of toxic effects and substantial cost.